Biohaven is a New Haven, Connecticut biopharmaceutical company developing treatments for immune, nerve and metabolic diseases. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 10 | HC Wainwright & Co. | Reiterated | Hold | |
| Sep 8 | RBC Capital | Downgrade | Hold | |
| Aug 12 | Morgan Stanley | Maintained | Buy | |
| Jun 29 | B of A Securities | Downgrade | Sell |
Whale Options Flow
90DNo whale options trades in BHVN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BHVN is in one of them and how their past BHVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BHVN in an article yet. Here's the latest on the wider market.
About Biohaven
Biohaven is a biopharmaceutical company based in New Haven, Connecticut. It develops treatments in immunology, neuroscience and oncology. Its main programs include a group of drugs that remove disease-causing proteins from the body for immune conditions such as Graves' disease and IgA nephropathy, a candidate for epilepsy, and a program for muscle and metabolic conditions, including obesity. Its treatments are aimed at patients with these diseases.
- Headquarters
- New Haven, CT